TINS - ETF AI Analysis
Top Page
Templeton International Insights ETF (TINS)
TINS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 5.65M
- Region
- Global Ex-U.S.
- Expense Ratio
- 0.55%
- Beta
- 0.78
- Issuer
- Templeton
- Inception Date
- Oct 21, 2025
- Dividend Yield
- 0.22%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
TINS Summary
Templeton International Insights ETF (TINS) is an actively managed fund that invests in stocks from many countries outside the U.S., with notable exposure to the UK, Germany, Japan, and more. It doesn’t track a fixed index, but instead follows an international total market theme, picking companies of all sizes across sectors like financials, technology, and healthcare. Well-known holdings include TSMC and AstraZeneca. Investors might consider TINS for global diversification and long-term growth potential. However, its value can go up and down with international stock markets and currency movements.
How much will it cost me?
The Templeton International Insights ETF (TINS) has an expense ratio of 0.55%, which means you’ll pay $5.50 per year for every $1,000 invested. This is higher than average because it is actively managed, meaning the fund’s managers actively select investments rather than following a preset index.
What would affect this ETF?
Templeton International Insights ETF (TINS) could benefit from global economic growth, particularly in emerging markets, and advancements in technology and healthcare sectors, which are key areas of its portfolio. However, it may face challenges from rising interest rates, geopolitical tensions, or regulatory changes in regions outside the U.S., which could negatively impact its holdings in financial and energy sectors. Diversification across industries and countries helps mitigate risks but does not eliminate them entirely.
TINS Top 10 Holdings
TINS leans heavily on a mix of global semiconductor and energy giants, with TSMC and Samsung acting as the fund’s growth engine thanks to their strong year-to-date runs, even if recent trading has been a bit mixed. On the energy side, BP and Shell have been steadily rising, giving the ETF a solid boost from higher-for-longer commodity sentiment. Financial names like ING and Euronext add a steady, income-friendly backbone, while big pharma holdings such as AstraZeneca and Sanofi are lagging, slightly dragging on performance. Overall, it’s a diversified, ex-U.S. play with a clear tilt toward chips, energy, and European financials.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 TSM | TSMC | 5.33% | $300.54K | $1.88T | 33.94% | 81Outperform |
 GB:BP | BP p.l.c. | 4.24% | $239.50K | GBP 96.96B | 40.09% | 71Outperform |
 GB:SMSN | Samsung Electronics | 3.67% | $207.17K | $1.07T | 127.79% | ―― |
 GB:SSE | SSE | 3.37% | $189.99K | GBP 31.89B | 36.50% | 74Outperform |
 FR:ENX | Euronext NV | 3.20% | $180.49K | EUR 17.52B | 43.46% | 65Neutral |
 GB:SHEL | Shell (UK) | 3.21% | $181.23K | GBP 229.30B | 40.01% | 73Outperform |
 NL:INGA | ING GROEP | 2.91% | $163.96K | EUR 78.77B | 27.71% | 61Neutral |
 GB:STAN | Standard Chartered | 2.87% | $162.07K | GBP 44.52B | 30.81% | 77Outperform |
 FR:SAN | Sanofi | 2.68% | $151.23K | EUR 95.65B | -9.46% | 75Outperform |
TINS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TINS, the sentiment is Positive. The current price of 28.12 is above the 20-day moving average (MA) of 28.02, below the 50-day MA of 28.64, and below the 200-day MA of 28.44, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 89.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TINS.
TINS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| TINS | $28.12 | $30.00(6.69% Upside) | $5.65M | 0.55% | 66Neutral |
 GIEQ | $40.99 | $49.11(19.83% Upside) | $61.89M | 0.30% | 66Neutral |
 PJIO | $57.60 | $80.26(39.34% Upside) | $59.07M | 0.54% | 64Neutral |
 AADR | $80.02 | $95.34(19.16% Upside) | $35.14M | 1.09% | 69Neutral |
 ABLG | $28.31 | ― | $13.06M | 0.54% | 62Neutral |
 VNIE | $24.46 | $28.96(18.41% Upside) | $8.65M | 0.60% | 63Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TINS | Templeton International Insights ETF | 28.12 | 3.21 | 12.90% | |
| GIEQ | Goldman Sachs Data Enhanced International Equity ETF | 40.98 | 0.49 | 1.21% | |
| PJIO | PGIM Jennison International Opportunities ETF | 57.60 | -6.29 | -9.84% | |
| AADR | AdvisorShares Dorsey Wright ADR ETF | 80.02 | -3.52 | -4.22% | |
| ABLG | Abacus Fcf International Leaders Etf | 28.31 | -2.44 | -7.93% | |
| VNIE | Vontobel International Equity Active ETF | 24.45 | -0.38 | -1.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.